Novo’s Ozempic Gains US Nod for Kidney Disease, Widening Use Novo Nordisk’s blockbuster drug Ozempic has received U.S.

Feb 02, 2025 - 21:53

Updated: 2 years ago

Novo’s Ozempic Gains US Nod for Kidney Disease, Widening UseNovo Nordisk’s blockbuster drug Ozempic has received U.S. regulatory approval for treating chronic kidney disease (CKD) in patients with type 2 diabetes, significantly expanding its potential use. This approval, granted by the U.S. Food and Drug Administration (FDA), is based on clinical trials demonstrating Ozempic’s efficacy in slowing the progression of kidney disease and reducing the risk of kidney failure, cardiovascular events, and death in this patient population.

Ozempic, a glucagon-like peptide-1 (GLP-1) receptor agonist, was initially approved for managing blood sugar levels in adults with type 2 diabetes and later gained popularity for its weight-loss benefits. The new indication for kidney disease marks a significant milestone, as it addresses a major complication of diabetes and could benefit millions of patients worldwide.

Chronic kidney disease is a common and serious complication of type 2 diabetes, often leading to kidney failure requiring dialysis or transplantation. By targeting both diabetes and its associated kidney complications, Ozempic offers a dual therapeutic approach, potentially improving outcomes and reducing healthcare costs.

This approval is expected to further boost sales of Ozempic, which has already become a top-selling drug for Novo Nordisk. It also highlights the growing recognition of GLP-1 receptor agonists as versatile treatments for a range of metabolic and cardiovascular conditions.